Alector, Inc. 8-K

What Happened Alector, Inc. announced that Glaxo Wellcome UK Limited (GSK) delivered written notice terminating the Collaboration and License Agreement between the companies; the termination is effective 180 days from the July 6, 2026 notice (January 2, 2027). The GSK collaboration covered development of progranulin‑elevating monoclonal antibodies latozinemab and nivisnebart, programs that experienced clinical setbacks: the Phase 3 INFRONT‑3 trial of latozinemab missed its co‑primary endpoint (announced Oct 21, 2025) and the Phase 2 PROGRESS‑AD trial of nivisnebart was discontinued after an interim futility analysis (announced Apr 29, 2026). Separately, on July 8, 2026 Alector repaid in full and terminated its Loan and Security Agreement with Hercules Capital and the lending group.

Key Details

• GSK delivered notice to terminate the collaboration on July 6, 2026; termination effective January 2, 2027 (180 days after notice).
• Latozinemab Phase 3 INFRONT‑3 missed its clinical co‑primary endpoint (announced Oct 21, 2025).
• Nivisnebart Phase 2 PROGRESS‑AD was discontinued after an interim futility analysis (announced Apr 29, 2026).
• Alector repaid $10,428,827.77 in aggregate principal, plus accrued interest and prepayment/end‑of‑term charges, and terminated the Loan Agreement on July 8, 2026.

Why It Matters This 8‑K signals a material change to Alector’s development partnerships and financing: the loss of the GSK collaboration removes a partner for key antibody programs and starts a 180‑day wind‑down before the agreement ends. The full repayment of the Hercules loan eliminates that debt obligation (reducing leverage) but also used company cash to retire the facility. Investors should view these as concrete, near‑term developments affecting Alector’s program support and capital structure; the company’s prior public announcements about the trial outcomes and the 10‑K exhibits (which include the full agreements) provide the detailed contractual context.